Follow-up Examinations for Occular Neoplasms and Pigmented Ocular Lesions, at the Dupont, West Virginia Plant.
Authors
Albert DA
Source
NIOSH 1980 Mar:49 pages
Link
NIOSHTIC No.
00112363
Abstract
Active and retired workers at the duPont Belle chemicals facility in West Virginia were ophthalmologically surveyed first in 1978 and again in 1979 in a follow-up study to identify cases of ocular neoplasms and determine the prevalence of ocular pigmented lesions. The workers were compared to individuals without occupational exposure to chemicals. A total of 1,149 patients were examined in 1978 of whom 591, 256 and 302 were active facility employees, retired facility employees, and nonindustrial worker participants, respectively. No choroidal melanomas were observed in the comparison populations. The prevalence of participants with conjunctival nevi, iris nevi, and chordal nevi amounted to 0.9 and and nonindustrial workers, respectively. In 1979, populations for re-examination were selected from all individuals having positive eye findings during the 1978 study. In the facility population, one patient with a suspected choroidal melanoma had evidence of size and color change since 1978. One other patient with choroidal nevi was suspected of having size and color change. In the comparison population, two patients had size or color change in choroidal nevi. Choroidal nevi in three patients in the facility group were not documented in 1978; two such lesions were found in the comparison group. Eight facility workers had iris nevi, which was not observed in 1978. In the control population, iris nevi not previously described were found in five patients. Many patients from the facility group and the comparison population with elevated pressure continued to have abnormal pressure. The author concludes that the patients with elevated intraocular pressure risk loss of vision and he recommends follow up examinations to maintain these pressures within safe limits.
Links with this icon indicate that you are leaving the CDC website.
The Centers for Disease Control and Prevention (CDC) cannot attest to the accuracy of a non-federal website.
Linking to a non-federal website does not constitute an endorsement by CDC or any of its employees of the sponsors or the information and products presented on the website.
You will be subject to the destination website's privacy policy when you follow the link.
CDC is not responsible for Section 508 compliance (accessibility) on other federal or private website.
For more information on CDC's web notification policies, see Website Disclaimers.
CDC.gov Privacy Settings
We take your privacy seriously. You can review and change the way we collect information below.
These cookies allow us to count visits and traffic sources so we can measure and improve the performance of our site. They help us to know which pages are the most and least popular and see how visitors move around the site. All information these cookies collect is aggregated and therefore anonymous. If you do not allow these cookies we will not know when you have visited our site, and will not be able to monitor its performance.
Cookies used to make website functionality more relevant to you. These cookies perform functions like remembering presentation options or choices and, in some cases, delivery of web content that based on self-identified area of interests.
Cookies used to track the effectiveness of CDC public health campaigns through clickthrough data.
Cookies used to enable you to share pages and content that you find interesting on CDC.gov through third party social networking and other websites. These cookies may also be used for advertising purposes by these third parties.
Thank you for taking the time to confirm your preferences. If you need to go back and make any changes, you can always do so by going to our Privacy Policy page.